US stock futures dip as Nvidia earnings spark little cheer
CHICAGO, IL – Tempus AI , Inc. (NASDAQ:TEM), a leading technology firm specializing in artificial intelligence with a market capitalization of $10.26 billion, announced the results of its 2025 Annual Meeting of Stockholders held on Tuesday. The company’s stock has experienced significant volatility, declining 9.5% in the past week despite a remarkable 75.5% gain year-to-date. InvestingPro analysis suggests the stock is currently trading above its Fair Value. The company, which is incorporated in Delaware and headquartered in Chicago, reported the approval of all proposals presented at the meeting as detailed in their definitive proxy statement filed on April 7, 2025.
The shareholders elected nine directors to serve until the 2026 Annual Meeting of Stockholders or until their successors are elected and qualified. This comes as the company maintains strong revenue growth of 43% over the last twelve months, though InvestingPro data shows the company is still working toward profitability with negative EBITDA of $658 million. The elected directors include Eric Lefkofsky, Peter J. Barris, Eric D. Belcher, Jennifer A. Doudna, Ph.D., David R. Epstein, Wayne A.I. Frederick, M.D., Scott Gottlieb, M.D., Theodore J. Leonsis, and Nadja West, M.D. The voting results showcased strong support, with all directors receiving a significant majority of the votes cast.
Additionally, the appointment of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with an overwhelming majority of votes in favor.
A significant development was the approval of the proposal to reincorporate the company from Delaware to Nevada, a strategic move that the Board of Directors has the discretion to abandon. The proposal received substantial support, although there was a notable number of votes against and abstentions.
Tempus AI emphasized that the reincorporation to Nevada would not result in any operational changes or affect the company’s name. The Board retains full discretion regarding the timing and execution of the reincorporation process.
The information provided is based on Tempus AI’s recent SEC filing and reflects the company’s commitment to transparency and adherence to corporate governance standards. With a moderate debt-to-equity ratio of 2.63 and overall Fair financial health score, the company faces both opportunities and challenges ahead. Discover more detailed insights and 6 additional key ProTips for TEM through InvestingPro’s comprehensive research report, part of its coverage of over 1,400 US stocks.
In other recent news, Tempus AI Inc. reported a strong performance in its first-quarter 2025 earnings, with revenue surging by 75.4% year-over-year to $255.7 million, surpassing the forecast of $248.5 million. The company also reported an earnings per share (EPS) of -$0.24, slightly better than the anticipated -$0.26. Morgan Stanley (NYSE:MS) raised its price target for Tempus AI to $65 from $60, maintaining an Overweight rating, following the company’s impressive first-quarter performance. The firm highlighted Tempus’s transition to its xT-CDx system and promising early traction in minimal residual disease (MRD) testing as key factors in its decision.
Tempus AI also announced a strategic collaboration with Boehringer Ingelheim to enhance cancer treatment research and development, leveraging its AI-powered platform. This partnership aims to integrate Tempus’s extensive de-identified database and analytical platform with Boehringer Ingelheim’s oncology pipeline. In another development, Tempus AI has partnered with Verastem (NASDAQ:VSTM) Oncology to develop a companion diagnostic test for recurrent low-grade serous ovarian cancer. This collaboration builds on the success of Verastem’s Phase 2 clinical trial and aims to improve treatment options for patients with this aggressive form of cancer.
Additionally, Tempus AI secured a $200 million contract from an expanded partnership with AstraZeneca (NASDAQ:AZN) and the Pathos Foundation, expected to drive medium-term growth in its Data and Services business. The company raised its full-year 2025 revenue guidance to $1.25 billion, projecting an 80% year-over-year growth. These developments underscore Tempus AI’s commitment to advancing precision medicine and improving patient outcomes in oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.